References
- Blade J, Rosinol L, Cibeira MT, et al. Hematopoietic stem cell transplantation for multiple myeloma beyond. Blood 2010;115: 3655–3663.
- Harousseau JL, Attal M, Avet-Loisseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139–3146.
- Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775–5782.
- Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013;31:3279–3287.
- Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with Bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15:5250–5257.
- San-Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2013;31:3696–3703.
- Richardson PG, Hungria VTM, Yoon SS, et al. Panorama 1: a randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2014;32(5 Suppl.): Abstract 8510.
- Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013;122:2331–2337.
- Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
- Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials:report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691–4695.
- Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus Dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet 2010;376:2075–2085.
- Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and Dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase III PETHEMA/GEM study. Blood 2012;120:1589–1596.